NanoViricides to Present Broad-Spectrum Antiviral Platform at LSX World Congress 2025

NanoViricides, Inc. (NYSE American: NNVC), a clinical-stage company developing broad-spectrum antiviral drugs designed to resist viral escape, will present at the Life Science Executive Partnering (LSX) World Congress 2025 in Boston on Wednesday, September 17, at 12:30 p.m. The presentation will focus on the company's innovative nanoviricide technology platform and its pipeline of drug candidates targeting multiple viral infections.

The company's lead drug candidate, NV-387, represents a significant advancement in antiviral therapy as a broad-spectrum treatment being developed for respiratory syncytial virus (RSV), COVID-19, long COVID, influenza, and other respiratory viral infections, as well as MPOX/smallpox infections. Another advanced candidate, NV-HHV-1, targets the treatment of shingles. The company is currently focused on advancing NV-387 into Phase II human clinical trials, though it cannot project an exact date for filing an Investigational New Drug (IND) application due to dependence on external collaborators and consultants.

NanoViricides' technology platform is based on intellectual property, technology, and proprietary know-how licensed from TheraCour Pharma Inc. through a Memorandum of Understanding that covers development of drugs for all antiviral infections, excluding cancer and similar diseases requiring different treatment approaches. The company holds broad, exclusive, sub-licensable field licenses for drugs developed in several licensed fields from TheraCour Pharma Inc., with its business model established at its foundation in 2005 focusing on licensing technology for specific application verticals of specific viruses.

The company's COVID-19 program includes two distinct candidates: NV-CoV-2 (API NV-387), which does not encapsulate remdesivir, and NV-CoV-2-R, which incorporates remdesivir encapsulated within its polymeric micelles. The company believes that since remdesivir is already FDA-approved, its drug candidate encapsulating remdesivir is likely to be approvable if safety profiles prove comparable. Additional development programs target oral and genital herpes, viral eye diseases including EKC and herpes keratitis, H1N1 swine flu, H5N1 bird flu, seasonal influenza, HIV, hepatitis C, rabies, dengue fever, and Ebola virus, among others.

NanoViricides holds a worldwide exclusive perpetual license to TheraCour's nanomedicine technology for several drugs with specific targeting mechanisms for the treatment of numerous human viral diseases, including HIV/AIDS, hepatitis B and C viruses, rabies, herpes simplex viruses, varicella-zoster virus, influenza viruses, dengue viruses, Japanese encephalitis virus, West Nile virus, Ebola/Marburg viruses, and certain coronaviruses. The company intends to obtain additional licenses for RSV, poxviruses, and/or enteroviruses if initial research proves successful. The latest news and updates relating to NNVC are available in the company's newsroom at https://ibn.fm/NNVC.

As with all pharmaceutical development, NanoViricides acknowledges that the path to drug approval is extremely lengthy and requires substantial capital, with no assurance that any candidates will demonstrate sufficient effectiveness and safety for human clinical development or that successful laboratory results will translate to successful clinical trials or commercial products. The presentation at LSX World Congress 2025 provides an opportunity for the scientific and investment communities to evaluate the potential impact of this innovative approach to antiviral therapy that addresses the critical challenge of viral escape resistance.